Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.

Katsuyuki Kiura, T. Ohnoshi, Masahiro Tabata, T. Shibayama, I. Kimura

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalActa Medica Okayama
Volume47
Issue number3
Publication statusPublished - Jun 1993

Fingerprint

Small Cell Lung Carcinoma
Doxorubicin
Cells
Pharmaceutical Preparations
Glutathione S-Transferase pi
Type II DNA Topoisomerase
Detoxification
Enzyme activity
P-Glycoprotein
Drug Resistance
Northern Blotting
Inhibitory Concentration 50
Glutathione
Assays
Cell Line
Messenger RNA
Enzymes
Growth
Population

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance. / Kiura, Katsuyuki; Ohnoshi, T.; Tabata, Masahiro; Shibayama, T.; Kimura, I.

In: Acta Medica Okayama, Vol. 47, No. 3, 06.1993, p. 191-197.

Research output: Contribution to journalArticle

@article{66a4ae38219a4b019f5136777ca17756,
title = "Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.",
abstract = "A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50{\%} determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance.",
author = "Katsuyuki Kiura and T. Ohnoshi and Masahiro Tabata and T. Shibayama and I. Kimura",
year = "1993",
month = "6",
language = "English",
volume = "47",
pages = "191--197",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Establishment of an adriamycin-resistant subline of human small cell lung cancer showing multifactorial mechanisms of resistance.

AU - Kiura, Katsuyuki

AU - Ohnoshi, T.

AU - Tabata, Masahiro

AU - Shibayama, T.

AU - Kimura, I.

PY - 1993/6

Y1 - 1993/6

N2 - A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance.

AB - A subline highly resistant to Adriamycin (SBC-3/ADM100) was isolated in vitro from the human small cell lung cancer cell line, SBC-3, by culturing in progressively higher concentrations of Adriamycin. The SBC-3/ADM100 cells were 106-fold more resistant to the drug than the parent cells in an inhibitory concentration of 50% determined by the MTT assay. The population-doubling time was much longer in SBC-3/ADM100 than in the parent cells. Northern blot hybridization revealed marked overexpression of the MDR1 mRNA in the resistant cells. P-glycoprotein overexpression and a decrease in intracellular accumulation of Adriamycin were demonstrated in SBC-3/ADM100, indicating that outward drug transport was the major mechanism of resistance in this subline. Additionally, a significant elevation of the intracellular glutathione content coupled with the glutathione S-transferase (GST) pi level and a decrease in DNA topoisomerase II (Topo II) activity were noted in this resistant subline. These results indicate that the mechanism of resistance to Adriamycin is multifactorial; involving altered growth characteristics, an enhanced outward transport, enhanced drug detoxification process, and decreased target enzyme activity. The resistant subline will serve as a useful tool in the search for ways to overcome drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=0027617091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027617091&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 191

EP - 197

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -